These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 1605898)

  • 1. Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.
    Günzler V
    Drug Saf; 1992; 7(2):116-34. PubMed ID: 1605898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide: current and potential clinical applications.
    Calabrese L; Fleischer AB
    Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide: a re-look.
    Grover JK; Vats V; Gopalakrishna R; Ramam M
    Natl Med J India; 2000; 13(3):132-41. PubMed ID: 11558112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide for erythema nodosum leprosum and other applications.
    Okafor MC
    Pharmacotherapy; 2003 Apr; 23(4):481-93. PubMed ID: 12680478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide: an alternative therapy for treatment of apthous ulcers (canker sores).
    Manesis DA
    STEP Perspect; 1995; 7(1):16-7. PubMed ID: 11362397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection.
    Paterson DL; Georghiou PR; Allworth AM; Kemp RJ
    Clin Infect Dis; 1995 Feb; 20(2):250-4. PubMed ID: 7742424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thalidomide: new uses for an old drug].
    Wu KL; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide for aphthous ulcers in HIV infection.
    Birnkrant D
    N Engl J Med; 1997 Oct; 337(15):1086-7. PubMed ID: 9324641
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential novel uses of thalidomide: focus on palliative care.
    Peuckmann V; Fisch M; Bruera E
    Drugs; 2000 Aug; 60(2):273-92. PubMed ID: 10983733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide: new preparation. For well-defined indications.
    Prescrire Int; 1998 Oct; 7(37):131-4. PubMed ID: 10848043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA
    N Engl J Med; 1997 May; 336(21):1487-93. PubMed ID: 9154767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide in the management of recurrent aphthous ulcerations in patients who are HIV-positive: a review and case reports.
    Shetty K
    Spec Care Dentist; 2005; 25(5):236-41. PubMed ID: 16454100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.
    Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N
    J Infect Dis; 1999 Jul; 180(1):61-7. PubMed ID: 10353862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promise of thalidomide: evolving indications.
    Joglekar S; Levin M
    Drugs Today (Barc); 2004 Mar; 40(3):197-204. PubMed ID: 15148528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thalidomide once more in the spotlight].
    de Jong-van den Berg LT; Rutgers J; Cornel MC
    Ned Tijdschr Geneeskd; 1998 Nov; 142(46):2509-12. PubMed ID: 10028338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.
    Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C
    J Infect Dis; 2001 Jan; 183(2):343-346. PubMed ID: 11120935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide: dermatological indications, mechanisms of action and side-effects.
    Wu JJ; Huang DB; Pang KR; Hsu S; Tyring SK
    Br J Dermatol; 2005 Aug; 153(2):254-73. PubMed ID: 16086735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current role of thalidomide in HIV-positive patients with recurrent aphthous ulcerations.
    Shetty K
    Gen Dent; 2007; 55(6):537-42. PubMed ID: 18050580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.
    Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL
    J Am Acad Dermatol; 1996 Dec; 35(6):969-79. PubMed ID: 8959957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide in oral aphthous ulceration in patients with HIV infection.
    Henriquet F; Roy MT; Repetto T; Fusco F
    Palliat Med; 1994; 8(3):255-6. PubMed ID: 7952375
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.